Podcasts about host charles turck

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Samuel Yamshon, MD The treatment landscape for large B-cell lymphoma (LBCL) is rapidly evolving due to the growing integration of bispecific antibodies into second-line care. While these agents offer promising, targeted options—not only for patients ineligible for CAR T-cell therapy, but also as complementary strategies in combination with chemoimmunotherapy—they raise important questions around sequencing, durability, and patient selection. Joining Dr. Charles Turck to explore the real-world implications of this evolving approach is Dr. Samuel Yamshon, Director of the Cellular Therapy Service and an Assistant Professor of Medicine at Weill Cornell Medicine in New York.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD CAR T-cell therapies have helped transform the treatment of aggressive lymphomas, but could they also change the game for slower-growing, harder-to-treat diseases like marginal zone lymphoma? Based on new data from the TRANSCEND FL study, liso-cel achieved a 95 percent overall response rate and sustained 24-month progression-free survival in relapsed/refractory marginal zone lymphoma. Here with Dr. Charles Turck to share the key efficacy and safety findings is Dr. Sairah Ahmed, Professor in the Department of Lymphoma and Myeloma and CAR T Program Director at MD Anderson Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Evandro Bezerra, MD As CAR T-cell therapy advances, so does the complexity of adverse event monitoring. Due to evolving insights into acute toxicities, infections, cytopenias, and secondary malignancies, both inpatient and outpatient care models are adapting to meet new standards. Joining Dr. Charles Turck to discuss practical strategies and emerging tools for managing post-CAR T toxicities across the continuum of care is Dr. Evandro Bezerra, Clinical Assistant Professor at Ohio State University Comprehensive Cancer Center in Columbus.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Forat Lutfi, MD Guest: Nilanjan Ghosh, MD, PhD For patients with relapsed/refractory large B-cell lymphoma, timely access to CAR T-cell therapy can be life-saving, but communication gaps between referring physicians and CAR T centers can lead to delays or missed opportunities. Fortunately, practical strategies like building strong referral networks, improving direct communication, and aligning on shared care responsibilities can streamline access and improve outcomes. Joining Dr. Charles Turck to share their insights on how we can bridge these communication gaps are Drs. Forat Lutfi and Nilanjan Ghosh. Dr. Lutfi is an Assistant Professor of Hematologic Malignancies and Cellular Therapeutics at University of Kansas Medical Center, and Dr. Ghosh is a Professor of Cancer Medicine at the Wake Forest University School of Medicine in Charlotte, North Carolina.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jacqueline Wong, MD, MSCR, FACOG For patients with endometriosis, treatment delays can profoundly impact both quality of life and clinical outcomes. Proactive strategies that address logistical barriers—such as prior authorizations—combined with education and multidisciplinary support are essential in improving care. Join Dr. Charles Turck and Dr. Jacqueline Wong as they explore practical approaches for managing this complex condition and navigating potential hurdles. Dr. Wong is a minimally invasive gynecologic surgeon and an Assistant Professor of Obstetrics and Gynecology in the School of Medicine at Oregon Health and Science University in Portland.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and navigate logistical barriers to ensure timely, equitable access. Joining Dr. Charles Turck to explore these critical considerations is Dr. Saira Ahmed, Associate Professor in the Department of Lymphoma and Myeloma and the CAR T Program Director in the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and navigate logistical barriers to ensure timely, equitable access. Joining Dr. Charles Turck to explore these critical considerations is Dr. Saira Ahmed, Associate Professor in the Department of Lymphoma and Myeloma and the CAR T Program Director in the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Guest: Komal Jhaveri, MD, FACP The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there's a lot we need to think about when selecting therapy, like the differences between selective and non-selective inhibitors, toxicity profiles, and shared decision-making. Joining Dr. Charles Turck to share their insights on those key considerations and how we can personalize care for patients with PI3Kα-mutated HR+/HER2- advanced breast cancer are Drs. Komal Jhaveri and Neil Iyengar. Dr. Jhaveri is the section head for the Endocrine Therapy Research Program in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and Dr. Iyengar is the Co-Director of the Breast Oncology Program at the Winship Cancer Institute at Emory University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limited by significant toxicities, including hyperglycemia, rash, and diarrhea. But now, mutation-specific PIK3CA inhibitors could help improve tolerability and adherence as well as simplify dosing strategies—all while maintaining efficacy. To learn more about the efficacy and safety of current and emerging PIK3CA-targeted therapies, Dr. Charles Turck speaks with Dr. Neil Iyengar, Co-Director of the Breast Oncology Program and Director of Cancer Survivorship Service at Winship Cancer Institute at Emory University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it's also associated with endocrine therapy resistance and more aggressive cancer growth. Given its prevalence and impact on outcomes, it's important to know how and when to test for this mutation and how emerging targeted therapies might change our approach in clinical practice. Joining Dr. Charles Turck to share her insights on PI3Kα testing and targeted therapies for HR+/HER2- advanced breast cancer is Dr. Hope Rugo, Director of the Women's Cancers Program, Division Chief of Breast Medical Oncology and Professor of the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it's also associated with endocrine therapy resistance and more aggressive cancer growth. Given its prevalence and impact on outcomes, it's important to know how and when to test for this mutation and how emerging targeted therapies might change our approach in clinical practice. Joining Dr. Charles Turck to share her insights on PI3Kα testing and targeted therapies for HR+/HER2- advanced breast cancer is Dr. Hope Rugo, Director of the Women's Cancers Program, Division Chief of Breast Medical Oncology and Professor of the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limited by significant toxicities, including hyperglycemia, rash, and diarrhea. But now, mutation-specific PIK3CA inhibitors could help improve tolerability and adherence as well as simplify dosing strategies—all while maintaining efficacy. To learn more about the efficacy and safety of current and emerging PIK3CA-targeted therapies, Dr. Charles Turck speaks with Dr. Neil Iyengar, Co-Director of the Breast Oncology Program and Director of Cancer Survivorship Service at Winship Cancer Institute at Emory University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Guest: Komal Jhaveri, MD, FACP The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there's a lot we need to think about when selecting therapy, like the differences between selective and non-selective inhibitors, toxicity profiles, and shared decision-making. Joining Dr. Charles Turck to share their insights on those key considerations and how we can personalize care for patients with PI3Kα-mutated HR+/HER2- advanced breast cancer are Drs. Komal Jhaveri and Neil Iyengar. Dr. Jhaveri is the section head for the Endocrine Therapy Research Program in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and Dr. Iyengar is the Co-Director of the Breast Oncology Program at the Winship Cancer Institute at Emory University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Whitney Trotter Ross, MD, MSCI Despite advances in endometriosis treatment, bias and stigma continue to delay diagnosis and disrupt care for many patients. Informed, empathetic care is key for supporting diverse patient populations. Dr. Charles Turck sits down with Dr. Whitney Ross to unpack how historical misconceptions still influence prescribing habits and discuss actionable strategies for counseling, selecting a treatment plan, and building trust. Dr. Ross is an Assistant Professor of Obstetrics and Gynecology in the Division of Minimally Invasive Gynecologic Surgery at Washington University in St. Louis.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Whitney Trotter Ross, MD, MSCI Despite advances in endometriosis treatment, bias and stigma continue to delay diagnosis and disrupt care for many patients. Informed, empathetic care is key for supporting diverse patient populations. Dr. Charles Turck sits down with Dr. Whitney Ross to unpack how historical misconceptions still influence prescribing habits and discuss actionable strategies for counseling, selecting a treatment plan, and building trust. Dr. Ross is an Assistant Professor of Obstetrics and Gynecology in the Division of Minimally Invasive Gynecologic Surgery at Washington University in St. Louis.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Manali Kamdar, MD Although CAR T-cell therapies have transformed the treatment of B-cell malignancies, a major logistical and socioeconomic barrier remains: patients are typically required to stay near a certified treatment center for at least 4 weeks after infusion to manage potential adverse events. So to help improve patient access, a recent study explored exactly when toxicities occur and whether post-infusion monitoring could be shortened without compromising safety. And based on the findings, it's time to rethink the 4-week monitoring window. To learn more about the study's results and what they mean for patient monitoring, safety, and broader outcomes, tune in to hear Dr. Charles Turck speak with Dr. Manali Kamdar, who authored a poster on this topic that was presented at the 2025 American Society of Clinical Oncology Annual Meeting.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Manali Kamdar, MD Although CAR T-cell therapies have transformed the treatment of B-cell malignancies, a major logistical and socioeconomic barrier remains: patients are typically required to stay near a certified treatment center for at least 4 weeks after infusion to manage potential adverse events. So to help improve patient access, a recent study explored exactly when toxicities occur and whether post-infusion monitoring could be shortened without compromising safety. And based on the findings, it's time to rethink the 4-week monitoring window. To learn more about the study's results and what they mean for patient monitoring, safety, and broader outcomes, tune in to hear Dr. Charles Turck speak with Dr. Manali Kamdar, who authored a poster on this topic that was presented at the 2025 American Society of Clinical Oncology Annual Meeting.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: John Koo, MD As the array of novel therapies for plaque psoriasis expands, a strategy to navigate treatment options is to focus on the specific needs of different patient groups, like Medicare-aged patients. ILUMYA® (tildrakizumab-asmn) is the only biologic for plaque psoriasis guaranteed to be covered under the medical benefit of Medicare, with no prior authorization and zero cost as a likely possibility. Join Dr Charles Turck and Dr John Koo as they share insights on the efficacy, safety, and accessibility of ILUMYA in this patient population. Dr. Koo is a Professor of Dermatology at the University of California at San Francisco School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP In addition to heavy menstrual bleeding, patients with uterine fibroids often deal with many other considerable effects on their physical and mental wellbeing. To provide optimal care, it's important to recognize the full impact of fibroids, communicate carefully about treatment options, and promote equitable access to care. Dr. Charles Turck sits down with Dr. Ayman Al-Hendy to learn more about how we can address the multifaceted burden of uterine fibroids. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP In addition to heavy menstrual bleeding, patients with uterine fibroids often deal with many other considerable effects on their physical and mental wellbeing. To provide optimal care, it's important to recognize the full impact of fibroids, communicate carefully about treatment options, and promote equitable access to care. Dr. Charles Turck sits down with Dr. Ayman Al-Hendy to learn more about how we can address the multifaceted burden of uterine fibroids. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP Despite longstanding reliance on surgery, recent advancements have reshaped our approach to uterine fibroids. However, common myths and misconceptions have limited the adoption of newer therapies, leaving many patients unaware of their available options. Join Dr. Charles Turck and Dr. Ayman Al-Hendy as they explain shifting treatment paradigms and patient education strategies in uterine fibroid care. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP Despite longstanding reliance on surgery, recent advancements have reshaped our approach to uterine fibroids. However, common myths and misconceptions have limited the adoption of newer therapies, leaving many patients unaware of their available options. Join Dr. Charles Turck and Dr. Ayman Al-Hendy as they explain shifting treatment paradigms and patient education strategies in uterine fibroid care. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jason Ackrivo, MD, MSCE Guest: Bethany Lussier, MD Respiratory decline in patients with neuromuscular diseases and mitochondrial myopathies can be challenging to identify, especially because its early signs may be subtle and vary from person to person. However, knowing how to evaluate a patient's respiratory function is key to improving outcomes and quality of life. Joining Dr. Charles Turck to discuss this importance and provide recommendations for optimizing respiratory care are Drs. Jason Ackrivo and Bethany Lussier. Dr. Ackrivo is an Assistant Professor of Medicine in Pulmonary, Allergy, and Critical Care at the Hospital of the University of Pennsylvania, and Dr. Lussier is an Associate Professor of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Pulmonary and Critical Care Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jason Ackrivo, MD, MSCE Guest: Bethany Lussier, MD Respiratory decline in patients with neuromuscular diseases and mitochondrial myopathies can be challenging to identify, especially because its early signs may be subtle and vary from person to person. However, knowing how to evaluate a patient's respiratory function is key to improving outcomes and quality of life. Joining Dr. Charles Turck to discuss this importance and provide recommendations for optimizing respiratory care are Drs. Jason Ackrivo and Bethany Lussier. Dr. Ackrivo is an Assistant Professor of Medicine in Pulmonary, Allergy, and Critical Care at the Hospital of the University of Pennsylvania, and Dr. Lussier is an Associate Professor of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Pulmonary and Critical Care Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Aaron Logan, MD, PhD Although acute lymphoblastic leukemia (ALL) is a relatively rare disease with fewer than 7,000 people diagnosed each year in the US,1,2 there's been a lot of progress in the management of B-cell ALL over the years. One key development comes from the E1910 Phase III trial, which explored the addition of blinatumomab to frontline consolidation chemotherapy for patients with Philadelphia chromosome-negative B-lineage ALL (B-ALL).3 Joining Dr. Charles Turck to discuss the impacts of this data on B-ALL clinical guidelines and practice is Dr. Aaron Logan. Dr. Logan is a Professor of Clinical Medicine in the Division of Hematology/Oncology and Director of the Hematologic Malignancies Tissue Bank at UCSF. References: National Cancer Institute. SEER Cancer Stat Facts: Acute Lymphocytic Leukemia (ALL). Accessed at https://seer.cancer.gov/statfacts/html/alyl.html on March 31, 2025 Dana-Farber Cancer Institute. Acute Lymphoblastic Leukemia (ALL). Accessed September 17, 2024. https://www.dana-farber.org/cancer-care/types/acute-lymphoblastic-leukemia Litzow MR, et al. Blood. 2022;140(suppl 2):LBA-1

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Hadfield, MD Subcutaneous cancer immunotherapies may offer a faster, more resource-efficient alternative to intravenous administration, improving patient convenience and accessibility while maintaining efficacy. However, careful monitoring for immunotherapy-related toxicities remains essential. Joining Dr. Charles Turck to discuss these key considerations for subcutaneous cancer immunotherapies is Dr. Matthew Hadfield, Assistant Professor of Medicine at Brown University/Alpert School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Hadfield, MD Subcutaneous cancer immunotherapies may offer a faster, more resource-efficient alternative to intravenous administration, improving patient convenience and accessibility while maintaining efficacy. However, careful monitoring for immunotherapy-related toxicities remains essential. Joining Dr. Charles Turck to discuss these key considerations for subcutaneous cancer immunotherapies is Dr. Matthew Hadfield, Assistant Professor of Medicine at Brown University/Alpert School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD With an urgent need to screen for cancer, clinical trials have shown that the multi-cancer early detection (MCED) test Galleri® can screen for more than 50 distinct cancer types in adults 50 and over and predict its origin. Questions have remained regarding the risk of cancer for those patients with a CSD MCED result, followed by a diagnostic evaluation that did not result in a cancer diagnosis and a second MCED test. Recent research was conducted to help address this gap, and now, Dr. Eric Klein joins Dr. Charles Turck to share the real-world outcomes following a Galleri MCED retest. Dr. Klein is a distinguished scientist at Grail and one of the elite investigators on the clinical studies that led to the development of the Galleri MCED test.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD With an urgent need to screen for cancer, clinical trials have shown that the multi-cancer early detection (MCED) test Galleri® can screen for more than 50 distinct cancer types in adults 50 and over and predict its origin. Questions have remained regarding the risk of cancer for those patients with a CSD MCED result, followed by a diagnostic evaluation that did not result in a cancer diagnosis and a second MCED test. Recent research was conducted to help address this gap, and now, Dr. Eric Klein joins Dr. Charles Turck to share the real-world outcomes following a Galleri MCED retest. Dr. Klein is a distinguished scientist at Grail and one of the elite investigators on the clinical studies that led to the development of the Galleri MCED test.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD With an urgent need to screen for cancer, clinical trials have shown that the multi-cancer early detection (MCED) test Galleri® can screen for more than 50 distinct cancer types in adults 50 and over and predict its origin. Questions have remained regarding the risk of cancer for those patients with a CSD MCED result, followed by a diagnostic evaluation that did not result in a cancer diagnosis and a second MCED test. Recent research was conducted to help address this gap, and now, Dr. Eric Klein joins Dr. Charles Turck to share the real-world outcomes following a Galleri MCED retest. Dr. Klein is a distinguished scientist at Grail and one of the elite investigators on the clinical studies that led to the development of the Galleri MCED test.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Anthony Stein, MD Could a novel triplet combination therapy offer a new path forward in acute myeloid leukemia (AML) treatment? A recent Phase 1B trial explored the potential of tagraxofusp, azacitidine, and venetoclax for AML patients. To discuss the findings on this triplet combination therapy, Dr. Charles Turck speaks with Dr. Anthony Stein, Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope in Duarte, California.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Anthony Stein, MD Could a novel triplet combination therapy offer a new path forward in acute myeloid leukemia (AML) treatment? A recent Phase 1B trial explored the potential of tagraxofusp, azacitidine, and venetoclax for AML patients. To discuss the findings on this triplet combination therapy, Dr. Charles Turck speaks with Dr. Anthony Stein, Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope in Duarte, California.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Yi Bin Chen, MD Guest: Olaf Penack, MD For the past several decades, standard treatment for acute graft-versus-host disease (aGVHD) has been systemic high-dose steroids.1 While essential in some ways to initially control aGVHD, steroids are not beneficial in the long run due to the immunosuppression and toxicities associated with high cumulative doses.1,2 So what can be done moving forward to improve first-line steroid response and minimize cumulative steroid exposure? Joining Dr Charles Turck to discuss the potential of nonimmunosuppressive steroid-sparing agents for the first-line treatment of aGVHD are Drs Yi Bin Chen and Olaf Penack. Dr Chen is the Director of the Hematopoietic Cell Transplant and Cell Therapy Program at Massachusetts General Hospital, and Dr Penack is a senior physician and principal investigator within Hematology and Oncology at Charité Berlin. References: Bell EJ, Yu J, Bhatt V, et al. Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease. Transplant and Cell Ther. 2022;28(10):707.e1-707.e7. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150-1163. © 2025 CSL BehringCMD-964-0016-JAN25

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Miguel-Angel Perales, MD Guest: Anna Sureda, MD, PhD Unfortunately, the treatment paradigm for acute graft-versus-host disease (aGVHD) has not changed for a couple of decades as steroids remain the first-line treatment.1 However, steroids are not a targeted therapy, and they have many side effects that are not well tolerated by patients, including life-threatening infections.1-3 Given these risks, it is important to know how to manage infections related to immunosuppression and optimize the care of patients with aGVHD. Joining Dr Charles Turck to discuss the current landscape of aGVHD management are Dr Miguel-Angel Perales and Dr Anna Sureda. Dr Miguel-Angel Perales is the Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center in New York, and Dr Sureda is the Head of Clinical Hematology at the University of Barcelona in Spain. References: Bell EJ, Yu J, Bhatt V, et al. Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease. Transplant Cell Ther. 2022;28(10):707.e1-707.e7. doi:10.1016/j.jtct.2022.04.014 Sullivan PW, Ghushchyan VH, Globe G, Sucher B. Health-related quality of life associated with systemic steroids. Qual Life Res. 2017;26(4):1037-1058. García-Cadenas I, Rivera I, Martino R, et al. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow …

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Stephen I. Pelton, MD In the last two pre-pandemic flu seasons, approximately half of hospitalizations from influenza in the US were in adults 65 and older.1,2 A recent real-world study evaluated the relative effectiveness of adjuvanted influenza vaccine versus high-dose vaccine in preventing test-confirmed influenza hospitalizations in this age group across three flu seasons between 2017 and 2020.3 Dr. Charles Turck sits down with Dr. Stephen Pelton, an author on this study, to explore the findings and their implications for influenza vaccination strategies in older adults. Dr. Pelton is a Professor of Pediatrics at the Boston University Chobanian and Avedisian School of Medicine. References: Pelton SI, Nguyen VH, Mould-Quevedo JF. The value of influenza vaccination in the older adult population. A stochastic model estimation of the benefit of vaccination to prevent the severe outcomes in the U.S. Poster presented at: IDWeek 2023; October 11-15; Boston, MA. Pelton SI, Mould-Quevedo JF, Nguyen VH. The impact of adjuvanted influenza vaccine on disease severity in the US: a stochastic model. Vaccines. 2023;11:1525. McGovern I, Chastek B, Bancroft T, et al. Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons. Int J Infect Dis. …

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Matasar, MD When treating relapsed or refractory large B-cell lymphoma (R/R LBCL) with CAR T-cell therapy, the risk of adverse events is a key consideration. Models such as PhasED-Seq and CAR-HEMATOTOX can help clinicians assess the patient's risk and personalize care plans regarding treatment selection and location, prophylactic regimen, and early intervention strategies. Tune in to hear Dr. Charles Turck and Dr. Matthew Matasar discuss the importance of these models in identifying individual factors, which can maximize the benefits of CAR T-cell therapy and reduce toxicities. Dr. Matasar is the Chief of the Division of Blood Disorders at Rutgers Cancer Institute and a Professor of Medicine at Rutgers Robert Wood Johnson Medical School.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD Guest: Caron A. Jacobson, MD The side effects associated with CAR T-cell therapy are very different than those seen with other cancer therapies and include cytokine-release syndrome (CRS) and neurotoxicity. It's important to know how to recognize the signs of these adverse events and treat patients with relapsed or refractory large B-cell lymphoma early to avoid drastic quality-of-life impacts. To help improve patient safety and decrease hospital utilization, Dr. Charles Turck speaks with Drs. Caron Jacobson and Sairah Ahmed about the proper identification and management of these side effects in patients receiving CAR T-cell therapy. Dr. Jacobson is the Medical Director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute in Boston, and Dr. Ahmed is an Associate Professor in the Department of Lymphoma and Myeloma Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston.

Guest: Tara Graff, DO, MS Host: Charles Turck, PharmD, BCPS, BCCCP While CAR T-cell therapy is an effective option for patients with certain blood cancers like lymphoma and myeloma, it's associated with two common adverse events: cytokine release syndrome and neurotoxicity. Given those risks, safety protocols have evolved over time to include strategies like aggressive hydration, prophylactic use of corticosteroids, early intervention with tocilizumab, and multidisciplinary care. Joining Dr. Charles Turck to share her insights into how we can lower the risks of CAR T-cell therapy is Dr. Tara Graff, a medical oncologist who leads a community-based clinical trial program at Mission Cancer and Blood in Des Moines, Iowa.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Laura Alder, MD The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it's important to identify biomarkers that can predict a patient's response to therapy. That's why the phase 1b TROPION-LUNG02 trial examined the effectiveness of Dato-DXd and HER3-DXd in the presence of predictive biomarkers. Joining Dr. Charles Turck to discuss the trial's findings and implications is Dr. Laura Alder, Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Laura Alder, MD The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it's important to identify biomarkers that can predict a patient's response to therapy. That's why the phase 1b TROPION-LUNG02 trial examined the effectiveness of Dato-DXd and HER3-DXd in the presence of predictive biomarkers. Joining Dr. Charles Turck to discuss the trial's findings and implications is Dr. Laura Alder, Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Thomas Egenod, MD In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2 study is evaluating the efficacy and safety of combining durvalumab, chemotherapy, and novel agents in the neoadjuvant setting as well as combining durvalumab with novel agents in the adjuvant setting. Joining Dr. Charles Turck to share the preliminary results regarding the safety, pathological complete response, and major pathological response rates of these two approaches is study investigator Dr. Thomas Egenod, who presented the NeoCOAST-2 study at the 2024 World Conference on Lung Cancer.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Thomas Egenod, MD In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2 study is evaluating the efficacy and safety of combining durvalumab, chemotherapy, and novel agents in the neoadjuvant setting as well as combining durvalumab with novel agents in the adjuvant setting. Joining Dr. Charles Turck to share the preliminary results regarding the safety, pathological complete response, and major pathological response rates of these two approaches is study investigator Dr. Thomas Egenod, who presented the NeoCOAST-2 study at the 2024 World Conference on Lung Cancer.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sun-Ho Lee, MD, PhD Recent research explored the development, validation, and implications of the GEM integrative risk score (GEM-IRS). To learn how this innovative model helps predict the future risk of Crohn's Disease in healthy first-degree relatives, Dr. Charles Turck speaks with Dr. Sun-Ho Lee, Assistant Professor and clinician scientist at the Inflammatory Bowel Disease Centre at Mount Sinai Hospital in Toronto, Canada.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sun-Ho Lee, MD, PhD Recent research explored the development, validation, and implications of the GEM integrative risk score (GEM-IRS). To learn how this innovative model helps predict the future risk of Crohn's Disease in healthy first-degree relatives, Dr. Charles Turck speaks with Dr. Sun-Ho Lee, Assistant Professor and clinician scientist at the Inflammatory Bowel Disease Centre at Mount Sinai Hospital in Toronto, Canada.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Phil Ayers, PharmD, BCNSP, FMSHP, FASHP Though 100% soybean oil was once the standard for lipid emulsions in parenteral nutrition, mixed lipid emulsions have become more popular over the last decade. But there are a variety of patient-specific factors to consider before determining which type of lipid emulsion is appropriate. Dr. Charles Turck sits down with Dr. Phil Ayers to compare the available options and recommend strategies for selecting and monitoring patients. Dr. Ayers is a Clinical Associate Professor at the University of Mississippi School of Pharmacy and the Chief of Clinical Pharmacy Services in the Department of Pharmacy at Baptist Medical Center in Jackson.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Phil Ayers, PharmD, BCNSP, FMSHP, FASHP When considering multi-chamber bag parenteral nutrition (MCB-PN), there are a variety of factors to consider, including the patients' hemodynamic stability and nutrient needs. After a patient is selected, their whole care team must be aware of common risks and challenges to ensure safe and effective delivery. Dr. Charles Turck is joined by Dr. Phil Ayers to discuss appropriate patient selection based on recent updates to ASPEN guidelines and safety considerations. Dr. Ayers is a Clinical Associate Professor at the University of Mississippi School of Pharmacy and the Chief of Clinical Pharmacy Services in the Department of Pharmacy at Baptist Medical Center in Jackson, MI.